MARKET WIRE NEWS

Beam Therapeutics: A Better Entry Point Is Likely Coming (Rating Downgrade)

Source: SeekingAlpha

2026-06-26 08:40:00 ET

Beam Therapeutics ( BEAM ) is a cutting-edge biotech company focused on finding curative treatments for diseases using a form of gene editing called “base editing”. Simplistically, this involves switching out one of the four DNA letters (e.g. A to G or C to T) to alter a person’s DNA and, theoretically, cure their disease. It has been characterized as a “pencil with an eraser”, whereas probably the better-known alternative, CRISPR/CAS9 gene editing, can be conceptualized as a “pair of scissors”. The latter technique involves cutting the DNA double helix which, again theoretically, could lead to off-target or unintended mutations ....

Read the full article on Seeking Alpha

For further details see:

Beam Therapeutics: A Better Entry Point Is Likely Coming (Rating Downgrade)
CRISPR Therapeutics AG

NASDAQ: CRSP

CRSP Trading

-1.28% G/L:

$47.21 Last:

1,156,457 Volume:

$47.78 Open:

mwn-press-release-boost Ad 900
?>

CRSP Latest News

July 10, 2026 01:20:00 pm
3 Reasons to Buy CRISPR Therapeutics Stock
$4,723,079,547
91,202,323
0.18%
215
N/A
Biotechnology & Life Sciences
Healthcare
CH
Zug

Check Your Online Brokerage For CRSP

Subscribe to Our Newsletter

Link Market Wire News to Your X Account

Download The Market Wire News App